Skip to content
NewsResearch

Anthropic acquires solo biotech Mithril Medicine after a Claude-run program worked in mice

· by

The short version

Anthropic's life sciences team disclosed lab results from six outside drug-development partners and acquired Mithril Medicine, a one-person biotech whose Claude-run muscular dystrophy program moved from idea to promising mouse results in under 18 months.

Anthropic acquires solo biotech Mithril Medicine after a Claude-run program worked in mice

Anthropic acquired Mithril Medicine, a one-person company whose founder used Claude to manage contracts, logistics, and experiments across 11 external labs, after that work took a candidate treatment for a rare form of muscular dystrophy from an early idea to promising results in mice in under 18 months, per Anthropic's October 27, 2026 progress report.

What

Anthropic's life sciences team used the report to disclose lab results from six outside drug-development partnerships it began earlier in 2026, alongside the Mithril acquisition and its own internal drug programs. Mithril's founder, Cody Tranbarger, now works at Anthropic continuing the muscular dystrophy research, and the company said a human clinical trial could start as soon as late 2028 if the drug candidates keep holding up, per the same report. Among the outside partners, BigHat Biosciences connected Claude to its automated lab system and ran about 1,010 molecule variants over roughly 10 weeks. The best resulting antibody fragments bound their targets more than 10 times more tightly, stayed stable at temperatures 18 degrees Celsius higher, and clumped together more than 100 times more slowly than the originals. Enveda had Claude review 1,061 pages of manufacturing documentation, catching all 11 issues human reviewers had already found plus seven they had missed, which cut review time 89%, from over 25 hours to under three, and let Claude draft one regulatory filing in four hours instead of the roughly three months a manual draft takes.

Claude is doing lab work now, not just sketching molecules

The jump here is from AI proposing candidate molecules, the use case Anthropic has emphasized in past research posts, to AI running the operational grind of an actual drug program. Claude reanalyzed BigHat's raw lab data after researchers suspected the standard stability metrics were misleading, triaged Enveda's regulatory paperwork, and coordinated outside labs for a single scientist at Mithril. A biotech evaluating Claude today should weigh it against that operational bar rather than against molecule-design demos alone. Anthropic also flagged that this work is still mostly preclinical, so none of the partner results yet show a drug succeeding in human trials.

Context and reactions

The disclosures extend a pharma push Anthropic formalized in September, when it announced a collaboration with Novo Nordisk to test its Claude Science workbench on the drugmaker's research workflows. Anthropic also named Bristol Myers Squibb as a newer partner, using Claude to assess clinical trial plans. "From a single prompt, Claude generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete," said Michael Pourdehnad, the company's senior vice president and head of early clinical development for hematology, oncology, and cell therapy, per Anthropic's report.

What to watch next

Whether Mithril's muscular dystrophy candidate clears the jump from mouse results to an actual human trial filing by Anthropic's stated late-2028 target, and whether any of the six outside partners publish results from candidates that have advanced past the preclinical stage.

Sources